Paper Details

  1. Home
  2. Paper Details

How safe is rucaparib in ovarian cancer?

Author: CosgroveCasey M, O'MalleyDavid M

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Rucaparib is a promising therapeutic option for women with recurrent ovarian cancer. The side effect profile of rucaparib is similar to or more favorable than other PARP inhibitors. Clinicians should be prepared for increasing utilization of PARP inhibitors in the recurrent setting and potentially upfront usage.
Paper Details　
Original Abstract of the Article :
<b>Introduction</b>: Rucaparib is increasingly being utilized for women with recurrent ovarian cancer both as treatment and maintenance therapy. Poly-ADP&#160;ribose&#160;polymerase (PARP) inhibitors like rucaparib are daily oral medication that exploit the DNA repair pathway. The most significant ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1080/14740338.2018.1550067

データ提供：米国国立医学図書館（NLM）

Rucaparib: A Promising Weapon in the Fight Against Ovarian Cancer

The field of [oncology] is constantly seeking new weapons in the fight against [ovarian cancer]. This study explores the potential of [rucaparib], a [poly-ADP ribose polymerase (PARP) inhibitor], as a treatment option for [recurrent ovarian cancer]. Researchers analyzed data from [phase 1, 2, and 3 clinical trials] investigating the safety and efficacy of rucaparib. They found that [rucaparib showed promising efficacy in prolonging survival] and [had a favorable side effect profile] compared to other PARP inhibitors. The study highlighted [the potential for increased utilization of PARP inhibitors] in both recurrent and upfront settings.

A New Hope for Ovarian Cancer Treatment

This research suggests that [rucaparib] could be a significant breakthrough in the treatment of ovarian cancer. The study's findings demonstrate [the potential of PARP inhibitors] to prolong survival and improve the quality of life for patients with this disease.

Navigating the Desert of Cancer Treatment

Fighting ovarian cancer can feel like a journey through a vast and unforgiving desert. This study provides a glimmer of hope for patients, offering a new weapon in the battle against this challenging disease.

Dr. Camel's Conclusion

This study reveals the potential of rucaparib as a promising treatment option for ovarian cancer. The researchers have unearthed a new oasis in the desert of cancer treatment, offering hope for patients seeking effective and safe therapies.

Date :
  1. Date Completed 2019-07-18
  2. Date Revised 2019-07-18
Further Info :

Pubmed ID

30449210

DOI: Digital Object Identifier

10.1080/14740338.2018.1550067

Related Literature

Article Analysis
・Side Effects of rucaparib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.